How A Side Effect Has Wiped Out 73% Of Neurogene's Value In A Week
How A Side Effect Has Wiped Out 73% Of Neurogene's Value In A Week · Investor's Business Daily

In This Article:

Neurogene stock collapsed, again, on Monday after the company scrapped the high dose of its experimental Rett Syndrome treatment.


Waiting for permission
Allow microphone access to enable voice search

Try again.